Inhibrx Biosciences Inc.

NASDAQ: INBX · Real-Time Price · USD
23.36
-0.58 (-2.42%)
At close: Aug 15, 2025, 12:36 PM

Inhibrx Biosciences Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
1.3M n/a 100K n/a 100K n/a 1.63M 119K 30K 17K 274K 278K 711K 915K 2.84M 2.51M 918K 863K
Cost of Revenue
n/a 675K -635K 761K 475K 360K 298K -560K 731K 722K 720K 719K 29.91M n/a n/a n/a n/a 16.44M
Gross Profit
n/a -675K 735K -761K -375K -360K 1.34M 679K -701K -705K -446K -441K -29.2M 915K 2.84M 2.51M 918K -15.57M
Operating Income
-27.39M -42.9M -49.93M -46.8M -160.9M -73.83M -88.29M -45.83M -41.34M -43.77M -35.5M -30M -34.6M -29.02M -19.4M -18.8M -19.8M -18.56M
Interest Income
2.12M 2.33M 2M 2.89M 2.74M 3.3M 4.7M 2.32M 2.41M 5.08M 5.34M 5.34M n/a n/a n/a n/a n/a n/a
Pretax Income
-28.65M -43.31M -47.87M -43.86M 1.86B -78.71M -91.97M -51.79M -47.05M -48.92M -40.92M -35.33M -37.73M -31.25M -21.19M -20.58M -20.71M -19.29M
Net Income
-28.65M -43.31M -47.87M -43.86M 1.86B -78.71M -93.6M -51.79M -47.05M -48.69M -40.91M -40.65M -37.73M -33.49M -21.19M -20.58M -20.71M -19.29M
Selling & General & Admin
6.42M 6.02M 16.66M 7.9M 93.37M 9.87M 7.79M 7.89M 7.26M 6.4M 5.32M 5.35M 5.4M 5.05M 3.65M 2.85M 2.85M 3.01M
Research & Development
22.27M 36.88M 33.37M 38.89M 67.63M 63.59M 81.84M 38.06M 34.11M 37.39M 30.45M 24.93M 29.91M 24.89M 18.61M 18.48M 17.9M 16.44M
Other Expenses
n/a -675K -689K n/a n/a n/a n/a -304K -217K -5.15M -5.42M -5.32M 17K -14K n/a -1K 5K 16K
Operating Expenses
28.69M 42.23M 49.34M 46.8M 161M 73.47M 89.63M 45.64M 41.37M 43.78M 35.77M 30.28M 35.31M 29.93M 22.24M 21.31M 20.72M 19.42M
Interest Expense
-3.14M -2.69M n/a n/a 5.36M 8.13M 8.22M 8.15M 7.91M 5.08M 5.34M 5.34M 3.15M 2.27M 1.78M 1.78M 914K 745K
Selling & Marketing Expenses
n/a n/a n/a n/a n/a -104K -46K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
n/a 42.9M 50.03M 46.8M 161M 73.83M 89.92M 45.95M 41.37M 43.78M 35.77M 30.28M 35.31M 29.93M 22.24M 21.31M 20.72M 19.42M
Income Tax Expense
2K n/a n/a n/a 2K 316.72K -4K 2K 5K -225K -1K 5.32M 4K 2.24M n/a n/a n/a 2K
Shares Outstanding (Basic)
15.47M 15.47M 14.48M 15.47M 14.48M 54.55M 54.03M 47.15M 43.64M 43.58M 43.27M 39.07M 39.04M 39.02M 38.58M 37.89M 37.82M 37.74M
Shares Outstanding (Diluted)
15.47M 15.47M 14.48M 15.47M 14.81M 54.55M 54.03M 47.15M 43.64M 43.58M 43.27M 39.07M 39.04M 39.02M 38.58M 37.89M 37.82M 37.74M
EPS (Basic)
-1.85 -2.8 -3.31 -2.84 128.35 -1.44 -1.73 -1.1 -1.08 -1.12 -0.95 -1.04 -0.97 -0.86 -0.55 -0.54 -0.55 -0.51
EPS (Diluted)
-1.85 -2.8 -3.31 -2.84 125.48 -1.44 -1.73 -1.1 -1.08 -1.12 -0.95 -1.04 -0.97 -0.86 -0.55 -0.54 -0.55 -0.51
EBITDA
-27.39M -42.9M -47.18M -43.1M 1.86B -70.22M -87.99M -43.33M -38.85M -41.06M -35.5M -30M -34.27M -28.67M -19.4M -18.5M -19.5M -18.25M
EBIT
n/a -40.62M -47.87M -43.86M 1.86B -70.58M -88.29M -43.64M -39.14M -41.35M -35.57M -29.98M -34.58M -28.98M -19.41M -18.8M -19.8M -18.54M
Depreciation & Amortization
n/a 675K 689K 760K 476K 360K 298K 304K 731K 295K 720K 719K 324K 344K 307K 299K 298K 291K